Landmark K
Institutt for farmakoterapi Postboks 1065 Blindern 0316 Oslo.
Tidsskr Nor Laegeforen. 2001 Feb 28;121(6):701-5.
In recent years, the expenses for medical antihypertensive therapy have increased considerably, the main reason being the switchover to newer and more expensive antihypertensive drugs.
Several recent studies which have compared the efficacy of the older, conventional drugs (thiazid diuretics and beta-blockers) with the newer agents (calcium blockers, angiotensin-converting enzyme (ACE) inhibitors), have shown that they are almost equipotent with regard to effects on blood pressure, morbidity and mortality. At lower doses, the metabolic effects of thiazide diuretics are minimal and probably without clinical significance, and the risk of developing diabetes mellitus type 2 does not seem to be increased.
The cheaper thiazide diuretics are still valuable drugs in the treatment of hypertension. If more than one agent is necessary to reduce blood pressure to the desired level, they can be combined with other antihypertensive agents.
近年来,医学抗高血压治疗费用大幅增加,主要原因是转而使用更新且更昂贵的抗高血压药物。
最近几项比较 older、传统药物(噻嗪类利尿剂和β受体阻滞剂)与新型药物(钙通道阻滞剂、血管紧张素转换酶(ACE)抑制剂)疗效的研究表明,它们在对血压、发病率和死亡率的影响方面几乎等效。在较低剂量下,噻嗪类利尿剂的代谢作用极小,可能无临床意义,且患2型糖尿病的风险似乎并未增加。
较便宜的噻嗪类利尿剂在高血压治疗中仍是有价值的药物。如果需要不止一种药物将血压降至理想水平,它们可与其他抗高血压药物联合使用。